New Approach To Treating Anthrax Significantly Improves Survival Rates

Armen Hareyan's picture

Anthrax Disease

Results of two Human Genome Sciences animal studies demonstrated the life-saving potential of its human monoclonal antibody drug ABthrax (raxibacumab). The results show that a single dose of ABthrax, administered without concomitant antibiotics, improved survival rates by up to 64 percent when administered after animals were symptomatic for anthrax disease as a result of inhalation exposure to massively lethal doses of anthrax spores.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.